Navigation Links
ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Date:9/19/2007

Results presented at the 43rd European Association for the Study of

Diabetes Annual Meeting

AMSTERDAM, The Netherlands, Sept. 19 /PRNewswire/ -- Results presented today at the 43rd Annual Meeting of the European Association for the Study of Diabetes demonstrate the ability of ACTOS(R) (pioglitazone HCl) to reduce the risk of ischemic cardiovascular disease in patients with type 2 diabetes. ACTOS is an oral antidiabetic agent for type 2 diabetes belonging to the thiazolidinedione (TZD) class of drugs.

Study Design and Results (PS130 / Abstract #1257)

This retrospective analysis of case records from a large managed care database of patients with diabetes showed that therapeutic regimens that included ACTOS were associated with reductions in the risk for stroke or myocardial infarction (MI) compared to non-thiazolidinedione therapies. The adjusted relative risk of stroke for the ACTOS group was 20 percent lower than that for the group not receiving ACTOS. Likewise, the risk of sustaining a heart attack over the study period was 38 percent lower in the patients receiving ACTOS than in those taking an antidiabetes drug regimen that did not include ACTOS.

"In this study, ACTOS was associated with reduced risk of heart attack and stroke," said Robert Spanheimer, M.D., Takeda Pharmaceuticals North America, Inc., senior medical director of diabetes and metabolism. "These outcomes - in a real world setting - are consistent with findings of no increase in total macrovascular events or death from PROactive, a prospective, randomized, controlled outcomes study."

Case records from January 2003 through June 2006 from a large managed care database of diabetes patients who were at least 45 years of age:

-- had not had a stroke or MI for the last six months and who were taking

either ACTOS (11,433 patients) with or without any other antidiabetes

treatment (excluding rosiglitazone, another member of the TZD class);

or

-- who were taking an antidiabetes drug regimen that did not include ACTOS

or rosiglitazone (55,273 patients).

The study endpoint was timed to the first stroke or MI or end of the study period, whichever occurred first.

Additional data presented include a post hoc analysis of the GLAI study, a six-month head-to-head study of patients treated with ACTOS and rosiglitazone examining blood glucose levels and lipid levels. The abstract examines three- month data from the study.

About ACTOS

ACTOS works by directly targeting insulin resistance, a condition in which the body does not efficiently use the insulin it produces to control blood glucose levels. ACTOS is taken once daily as an adjunct to diet and exercise, and is approved for use for type 2 diabetes as monotherapy to lower blood glucose and in combination therapy with insulin, sulfonylureas, or metformin.

Important Safety Information About ACTOS(R) (pioglitazone HCl)

The prescription medication ACTOS is used along with diet and exercise to lower blood sugar (glucose) in adults with type 2 diabetes. ACTOS is taken once daily either alone or in combination with insulin, sulfonylureas, or metformin.

ACTOS is not for everyone. Certain patients with heart failure should not start taking ACTOS. ACTOS can cause or worsen congestive heart failure. Talk to your doctor immediately if you experience rapid weight gain, fluid retention, or shortness of breath.

Do not take ACTOS if you have active liver disease. Your doctor should perform a blood test to check for liver problems before you start ACTOS and periodically thereafter. Talk to your doctor immediately if you experience nausea, vomiting, stomach pain, tiredness, loss of appetite, dark urine, or yellowing of the skin. If you are of childbearing age, talk to your doctor before taking ACTOS, as it could increase your chance of becoming pregnant. Some people taking ACTOS may experience flulike symptoms, mild-to-moderate swelling of legs and ankles, and anemia. When taking ACTOS with insulin or sulfonylureas, you may be at risk for low blood sugar. Patients with diabetes should have regular eye exams. If you experience vision problems, consult your doctor immediately. Very rarely, some patients have experienced visual changes while taking ACTOS.

Please visit the ACTOS Web site at http://www.actos.com for Complete Prescribing Information.

Takeda Pharmaceuticals North America, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. In the United States, Takeda currently markets oral diabetes, insomnia, and gastroenterology treatments, and through the Takeda Global Research & Development Center, Inc., the company has a robust pipeline with compounds in development for diabetes, cardiovascular disease, and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit http://www.tpna.com.

ACTOS(R) (pioglitazone HCl) is a registered trademark of Takeda Pharmaceutical Company Limited and used under license by Takeda Pharmaceuticals North America, Inc.


'/>"/>
SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 2016 According to the 2016 ... driving ambulatory blood pressure monitoring system market growth. With ... ability to respond to different pressure rates, leading to ... to various cardiovascular disorders such as heart failure, stroke, ... are growing in prevalence each year. WHO estimates that ...
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/25/2016)... -- FDA 510(k) clearance covers Confocal ... urological and surgical applications Mauna Kea ... the multidisciplinary confocal laser endomicroscopy (CLE) platform, today ... with the 12 th 510(k) clearance from ... new FDA clearance covers Confocal Miniprobes indicated for ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... To ... solutions to the healthcare industry, The University of Scranton is adding a Certificate ... path to a career in rapidly growing field of healthcare information. , ...
(Date:5/30/2016)... ... May 30, 2016 , ... As the CDC relaxes its ... and their efforts to keep their households lice free. , According to a ... new policies that keep kids in the classroom despite the fact that they may ...
(Date:5/30/2016)... ... 30, 2016 , ... Shaolin Institute officially starts the annual ... intensive summer training camp starts on June 17th on Shaolin Institute Atlanta Campus. ... a fun and unique experience with an opportunity to learn KungFu martial arts ...
(Date:5/29/2016)... ... May 29, 2016 , ... Whole Health Supply is happy to announce ... clipper is available to the public. This is an unusual clipper because it opens ... average clipper. , Everything about this product is concentrated on ease of use, functionality ...
(Date:5/28/2016)... Aliso Viejo, California (PRWEB) , ... May 28, 2016 , ... ... just need to drag and drop a preset onto their media," said Christina Austin ... from Pixel Film Studios, editors can quickly and easily add stylish color grades to ...
Breaking Medicine News(10 mins):